Drug (Brand names) | Dose† | Proven Fracture Reduction* | Indication |
---|---|---|---|
Alendronate (Fosamax) | 10 mg daily, 70 mg weekly | Vertebral, hip, nonvertebral | Postmenopausal women, men; glucocorticoid-induced osteoporosis |
Risedronate (Actonel) | 5 mg daily, 35 mg weekly, 75 mg 2 days/month | Vertebral, hip, nonvertebral | Postmenopausal women, men; glucocorticoid-induced osteoporosis |
Ibandronate (Boniva) | 2.5 mg daily, 150 mg monthly, 3 mg IV every 3 months | Vertebral, nonvertebral | Postmenopausal women |
Zoledronic acid (Reclast, Zometa) | 5 mg IV yearly | Vertebral, hip, nonvertebral | Postmenopausal women |
Raloxifene (Evista) | 60 mg daily | Vertebral | Postmenopausal women |
Salmon calcitonin (Miacalcin, Fortical) | 200 U intranasally daily | Vertebral | Postmenopausal women |
Teriparatide (Forteo) | 20 mcg subcutaneously daily for ≤2 years | Vertebral, nonvertebral | Postmenopausal women |
Note:—IV indicates intravenous.
* In postmenopausal women with osteoporosis.
† Oral unless otherwise noted.